Galectin Therapeutics Inc (GALT) shareholders
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Richard E. Uihlein | 54,673,646 | 49.30% | 13D (active) amendment | Jul 31, 2026 |
| James C. Czirr Joint filing with 10X Fund, L.P. (9.60%), 10X Capital Management, LLC (9.60%) | 7,061,115 | 11.40% | 13D (active) amendment | Sep 22, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GALT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,988,353 | 2.96% | $13.87M | +2,189,116 | 0.00% |
| Vanguard Capital Management LLC | 2,168,065 | 2.15% | $10.06M | +201,523 | 0.00% |
| Geode Capital Management, LLC | 1,308,394 | 1.30% | $6.07M | +695,608 | 0.00% |
| Osaic Holdings, Inc. | 1,203,725 | 1.19% | $5.59M | +81,055 | 0.01% |
| Marshall Wace, Llp | 831,010 | 0.82% | $3.86M | −388,902 | 0.00% |
| Wealthspire Advisors, LLC | 721,788 | 0.72% | $3.35M | – | 0.02% |
| State Street Corp | 567,779 | 0.56% | $2.63M | +309,347 | 0.00% |
| Commonwealth Equity Services, LLC | 407,113 | 0.40% | $1.89M | +40,000 | 0.00% |
| Northern Trust Corp | 386,545 | 0.38% | $1.79M | +256,097 | 0.00% |
| Vanguard Fiduciary Trust Co | 366,476 | 0.36% | $1.70M | +62,235 | 0.00% |
| Vanguard Portfolio Management LLC | 327,766 | 0.33% | $1.52M | New | 0.00% |
| Two Sigma Investments, LP | 318,245 | 0.32% | $1.48M | −148,818 | 0.00% |
| LPL Financial LLC | 285,380 | 0.28% | $1.32M | +18,180 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 261,296 | 0.26% | $1.21M | +132,648 | 0.00% |
| Sovran Advisors, LLC | 257,997 | 0.26% | $874.61K | +167 | 0.07% |
| Geneos Wealth Management Inc. | 240,427 | 0.24% | $1.12M | −500 | 0.02% |
| UBS Group AG | 219,319 | 0.22% | $1.02M | +39,578 | 0.00% |
| Retirement Guys Formula LLC | 211,053 | 0.21% | $979.29K | +23,991 | 0.37% |
| Citadel Advisors LLC | 198,701 | 0.20% | $921.97K | −91,659 | 0.00% |
| Susquehanna International Group, Llp | 177,197 | 0.18% | $822.19K | −378,505 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 98 | 16M | 15.6% | 20 / 32 | 23 / 20 | 5M | 3M |
| Q1 2026 | 99 | 14M | 13.8% | 19 / 31 | 23 / 15 | 6M | 1M |
| Q4 2025 | 98 | 12M | 11.5% | 25 / 28 | 22 / 10 | 2M | 1M |
| Q3 2025 | 84 | 10M | 10.3% | 15 / 22 | 25 / 16 | 2M | 2M |
| Q2 2025 | 86 | 11M | 10.4% | 15 / 25 | 20 / 21 | 2M | 2M |
| Q1 2025 | 93 | 10M | 10.3% | 14 / 18 | 30 / 12 | 1M | 1M |
| Q4 2024 | 94 | 10M | 10.0% | 21 / 35 | 12 / 6 | 1M | 1M |
| Q3 2024 | 79 | 10M | 9.7% | 14 / 20 | 18 / 4 | 2M | 0M |
| Q2 2024 | 73 | 10M | 9.4% | 23 / 19 | 10 / 9 | 2M | 1M |
| Q1 2024 | 59 | 8M | 7.9% | 4 / 18 | 9 / 11 | 1M | 0M |
| Q4 2023 | 66 | 7M | 7.3% | 9 / 10 | 16 / 3 | 1M | 2M |
| Q3 2023 | 60 | 9M | 9.0% | 5 / 12 | 9 / 4 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
57 funds held GALT in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GALT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,521,443 | 1.51% | $7.06M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 951,470 | 0.94% | $4.41M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 594,705 | 0.59% | $2.76M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 520,365 | 0.52% | $1.55M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 309,874 | 0.31% | $1.44M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 271,585 | 0.27% | $684.39K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 160,592 | 0.16% | $745.15K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 116,397 | 0.12% | $345.70K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 112,988 | 0.11% | $524.26K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 95,489 | 0.09% | $240.63K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 89,577 | 0.09% | $415.64K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 78,302 | 0.08% | $197.32K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 63,710 | 0.06% | $189.22K | 0.00% | Jul 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 48,031 | 0.05% | $222.86K | 0.00% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 47,686 | 0.05% | $221.26K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joel Lewis | President and CEO, Director | 778,260 | 0.77% | Jan 22, 2026 |
| Khurram Jamil | Chief Medical Officer | 16,250 | 0.02% | Jul 16, 2026 |
| Jack W. Callicutt | Chief Financial Officer | 7,614 | 0.01% | Jan 21, 2026 |
| Richard E. Uihlein | Director, 10% owner | 52,523,297 | 52.08% | Aug 4, 2026 |
| Harold H. Shlevin | Director | 28,768 | 0.03% | Jun 30, 2026 |
| Henry Brem | Director | 0 | – | Mar 17, 2026 |
| Kary Eldred | Director | 70,107 | 0.07% | Feb 9, 2026 |
| Benjamin Carson Sr | Director | – | – | Jan 21, 2026 |
| Gilbert F. Amelio | Director | 60,614 | 0.06% | Jan 21, 2026 |
| Gilbert S. Omenn | Director | 66,769 | 0.07% | Jan 21, 2026 |
| Elissa J. Schwartz | Director | 1,000 | 0.00% | Jan 21, 2026 |
| Richard A. Zordani Jr. | Director | 44,083 | 0.04% | Jan 21, 2026 |
| Kevin D. Freeman | Director | 137,269 | 0.14% | Jan 21, 2026 |
| Marc Rubin | Director | 13,581 | 0.01% | Jan 27, 2025 |
| 10X Fund, L.P. | 10% owner | 12,091,147 | 11.99% | Dec 18, 2025 |
| James C. Czirr | 10% owner | 11,536,664 | 11.44% | Dec 18, 2025 |
| 10X Capital Management, LLC | 10% owner | 8,319,924 | 8.25% | Dec 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard E. Uihlein Director, 10% owner | Jul 31, 2026 | Option exercise | +31,825,235 | $3.00 | $95.48M | 42,162,911 |
| Richard E. Uihlein Director, 10% owner | Jul 31, 2026 | Option exercise | +2,550,932 | $4.05 | $10.33M | 44,713,843 |
| Khurram Jamil Chief Medical Officer | Jul 14, 2026 | Option exercise | +16,250 | $3.04 | $49.40K | 16,250 |
| Khurram Jamil Chief Medical Officer | Jul 14, 2026 | Sale(10b5-1 plan) | −16,250 | $5.13 | $83.36K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 29, 2026 | Option exercise | +47,467 | $2.50 | $118.67K | 47,467 |
| Khurram Jamil Chief Medical Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −47,467 | $5.04 | $239.23K | 0 |
| Harold H. Shlevin Director | Jun 29, 2026 | Option exercise | +22,268 | $1.23 | $27.39K | 28,768 |
| Harold H. Shlevin Director | Jun 29, 2026 | Sale(10b5-1 plan) | −22,268 | $5.04 | $112.23K | 6,500 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Option exercise | +2,533 | $2.50 | $6.33K | 2,533 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −2,533 | $5.00 | $12.67K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −2,037 | $5.00 | $10.19K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Option exercise | +2,037 | $2.20 | $4.48K | 2,037 |
| Harold H. Shlevin Director | Jun 26, 2026 | Sale(10b5-1 plan) | −7,732 | $5.00 | $38.66K | 6,500 |
| Harold H. Shlevin Director | Jun 26, 2026 | Option exercise | +7,732 | $1.23 | $9.51K | 14,232 |
| Khurram Jamil Chief Medical Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −7,557 | $3.14 | $23.73K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 23, 2026 | Option exercise | +7,557 | $1.23 | $9.30K | 7,557 |
| Khurram Jamil Chief Medical Officer | May 26, 2026 | Option exercise | +568 | $1.23 | $699 | 568 |
| Khurram Jamil Chief Medical Officer | May 26, 2026 | Sale(10b5-1 plan) | −568 | $3.10 | $1.76K | 0 |
| Kary Eldred Director | Feb 6, 2026 | Buy | +300 | $2.70 | $810 | 65,682 |
| Richard E. Uihlein Director, 10% owner | Jan 16, 2026 | Award | +13,158 | $3.04 | $40.00K | 10,332,676 |
| Jack W. Callicutt Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −20,354 | $3.67 | $74.70K | 7,614 |
| Joel Lewis President and CEO, Director | Jan 6, 2026 | Sale(10b5-1 plan) | −37,698 | $3.58 | $134.96K | 832,592 |
| Khurram Jamil Chief Medical Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −21,446 | $3.65 | $78.28K | 0 |
| Joel Lewis President and CEO, Director | Jan 5, 2026 | – | −56,332 | $3.88 | $218.57K | 776,260 |
| Jack W. Callicutt Chief Financial Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −25,732 | $3.90 | $100.35K | 27,968 |
| Joel Lewis President and CEO, Director | Jan 5, 2026 | Sale(10b5-1 plan) | −27,731 | $3.91 | $108.43K | 870,290 |
| Khurram Jamil Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −25,499 | $3.90 | $99.45K | 21,446 |
| Jack W. Callicutt Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −13,914 | $4.20 | $58.44K | 53,700 |
| Jack W. Callicutt Chief Financial Officer | Jan 2, 2026 | Option exercise | +60,000 | – | – | 67,614 |
| Joel Lewis President and CEO, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −18,571 | $4.20 | $78.00K | 898,021 |
| Joel Lewis President and CEO, Director | Jan 2, 2026 | Option exercise | +84,000 | – | – | 916,592 |
| Khurram Jamil Chief Medical Officer | Jan 2, 2026 | Option exercise | +60,000 | – | – | 60,000 |
| Khurram Jamil Chief Medical Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −13,055 | $4.20 | $54.83K | 46,945 |
| Khurram Jamil Chief Medical Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −8,125 | $4.07 | $33.07K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 31, 2025 | Option exercise | +8,125 | $1.23 | $9.99K | 8,125 |
| Kary Eldred Director | Dec 23, 2025 | Buy | +700 | $3.73 | $2.61K | 65,382 |
| Kevin D. Freeman Director | Dec 23, 2025 | Buy | +5,500 | $3.55 | $19.53K | 55,269 |
| Kevin D. Freeman Director | Dec 23, 2025 | Buy | +5,500 | $3.55 | $19.53K | 55,269 |
| Kary Eldred Director | Dec 23, 2025 | Buy | +700 | $3.73 | $2.61K | 65,382 |
| Kevin D. Freeman Director | Dec 23, 2025 | Buy | +5,500 | $3.55 | $19.53K | 55,269 |
| Harold H. Shlevin Director | Dec 17, 2025 | Sale(10b5-1 plan) | −19,793 | $7.04 | $139.34K | 11,206 |
| Harold H. Shlevin Director | Dec 17, 2025 | Sale(10b5-1 plan) | −4,706 | $7.04 | $33.13K | 6,500 |
| Harold H. Shlevin Director | Dec 17, 2025 | Option exercise | +20,000 | $1.98 | $39.60K | 31,206 |
| Joel Lewis President and CEO, Director | Dec 17, 2025 | Option exercise | +7,829 | $2.86 | $22.39K | 840,421 |
| Joel Lewis President and CEO, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −7,829 | $7.06 | $55.27K | 832,592 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −4,479 | $7.04 | $31.53K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −6,463 | $7.04 | $45.50K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Option exercise | +8,500 | $2.50 | $21.25K | 8,500 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −8,500 | $7.04 | $59.84K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Option exercise | +6,463 | $2.20 | $14.22K | 6,463 |
| James C. Czirr 10% owner | Dec 16, 2025 | Sale | −30,681 | $6.66 | $204.34K | 5,614,457 |
| Harold H. Shlevin Director | Dec 15, 2025 | Sale(10b5-1 plan) | −8,417 | $6.30 | $53.03K | 11,206 |
| Harold H. Shlevin Director | Dec 15, 2025 | Option exercise | +8,417 | $4.16 | $35.01K | 19,623 |
| Harold H. Shlevin Director | Dec 12, 2025 | Option exercise | +19,793 | $4.16 | $82.34K | 30,999 |
| Harold H. Shlevin Director | Dec 12, 2025 | Sale(10b5-1 plan) | −19,793 | $6.27 | $124.10K | 11,206 |
| Harold H. Shlevin Director | Dec 9, 2025 | Sale(10b5-1 plan) | −16,790 | $6.27 | $105.27K | 11,206 |
| Harold H. Shlevin Director | Dec 9, 2025 | Option exercise | +16,790 | $4.16 | $69.85K | 27,996 |
| Harold H. Shlevin Director | Dec 8, 2025 | Sale(10b5-1 plan) | −20,000 | $6.00 | $120.00K | 11,206 |
| Harold H. Shlevin Director | Dec 8, 2025 | Option exercise | +20,000 | $1.11 | $22.20K | 31,206 |
| Harold H. Shlevin Director | Dec 8, 2025 | Sale(10b5-1 plan) | −35,000 | $6.02 | $210.70K | 11,206 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Galectin Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 57,461 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Harold H. Shlevin Director | Jun 29, 2026 | 22,268 | $112.21K | Jun 29, 2026 | STOCK OPTION EXERCISE |
| Harold H. Shlevin DIRECTOR | Jun 26, 2026 | 7,732 | $38.68K | Jun 26, 2026 | STOCK OPTION EXERCISE |
| Khurram Jamil Officer | Jun 26, 2026 | 68,287 | $341.44K | Jun 26, 2026 | Stock Option Exercise |
| Khurram Jamil Officer | Jun 23, 2026 | 8,125 | $25.50K | Jun 23, 2026 | Stock Option Exercise |
| Harold H. Shlevin Director | Jan 6, 2026 | 441,500 | $1.84M | Jan 2, 2026 | PURCHASE |
| Jack W. Callicutt Officer | Jan 5, 2026 | 60,000 | $252.00K | Jan 2, 2026 | Restricted Stock Units |
| Joel Lewis Officer | Jan 2, 2026 | 84,000 | $352.80K | Jan 2, 2026 | Restricted Stock Units |
| Khurram Jamil Officer | Jan 2, 2026 | 60,000 | $252.00K | Jan 2, 2026 | Restricted Stock Units |
| Jack W. Callicutt Officer | Jan 2, 2026 | 141,206 | $593.07K | Jan 2, 2026 | Restricted Stock Units |
| Khurram Jamil Officer | Dec 31, 2025 | 8,125 | $33.31K | Dec 31, 2025 | Option Exercise |
| Joel Lewis Officer | Dec 17, 2025 | 40,000 | $282.24K | Dec 17, 2025 | Option Exercise |
| Khurram Jamil Officer | Dec 17, 2025 | 21,479 | $151.21K | Dec 17, 2025 | Option Exercise |
| Harold H. Shlevin DIRECTOR | Dec 17, 2025 | 24,706 | $172.22K | Dec 17, 2025 | STOCK OPTION |
| Harold H. Shlevin DIRECTOR | Dec 15, 2025 | 19,793 | $122.99K | Dec 12, 2025 | STOCK OPTION |
| Harold H. Shlevin DIRECTOR | Dec 15, 2025 | 8,417 | $52.54K | Dec 15, 2025 | STOCK OPTION |
See a number that looks wrong?